Project

Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial

Completed · 2006 until 2010

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2006
End Date
2010
Financing
Others
Study Design
multicenter phase I trial that will include a minimum of 3 and a maximum of 24 patients
Keywords
maximum tolerated dose (MTD), chemotherapy resistant CD20+ lymphoma
Partner
Dr. med. Michèle Voegeli Kantonsspital Liestal
Brief description/objective

Identification of the maximum tolerated dose (MTD) of melphalan in combination with ibritumomab tiuxetan in patients ≥ 65 years with relapsed or chemotherapy resistant CD20+ lymphoma.
Evaluation of feasibility and safety of ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in the same patient population.
Additional research question: Feasibility of stem cell mobilization with vinorelbine in patients ≥ 65 years with lymphoma after salvage treatment.